Skip to main content
Premium Trial:

Request an Annual Quote

Persephone Biosciences, Janssen Biotech Ink Biomarker Discovery Agreement

NEW YORK — Microbiome research firm Persephone Biosciences said on Tuesday that it has signed an agreement to use patient samples from a Janssen Biotech clinical trial for biomarker discovery.

Under the terms of the deal, Persephone will have access to stool samples obtained using its proprietary collection kit from patients participating in an undisclosed Janssen cancer clinical trial. Persephone will analyze the samples and have the exclusive right to license any biomarkers discovered.

Additional terms were not disclosed.

"We are excited for this collaboration as it will provide us with an opportunity not only to further our understanding of the microbiome's role in disease, but also to build upon the growing body of evidence highlighting the microbiome's role in influencing patient treatment outcomes," Persephone cofounder and CEO Stephanie Culler said in a statement.

San Diego-based Persephone is developing precision immunotherapeutics using microbiome and other medical data from stool and blood samples collected from healthy individuals and cancer patients. Its technology platform is based on population-scale, observational clinical trials in conjunction with advanced multiomics analyses and machine learning.

Earlier this year, the company launched a clinical study examining the impact of the gut microbiome on immune responses to COVID-19 vaccination.

Persephone's labs are housed within Johnson & Johnson Innovation. Janssen is a subsidiary of Johnson & Johnson.

The Scan

Just Breathing

A new analysis suggests that most Mycobacterium tuberculosis is spread by aerosols from breathing, rather than by coughing, the New York Times reports.

Just Like This One

NPR reports that the World Health Organization has hired a South African biotech company to recreate mRNA vaccine for SARS-CoV-2 that is similar to the one developed by Moderna.

Slow Start

The Wall Street Journal reports that Biogen's Alzheimer's disease treatment had revenues for July through September that totaled $300,000.

Genome Research Papers on Cancer Chromatin, Splicing in the Thymus, Circular RNAs in Cancer

In Genome Research this week: analysis of bivalent chromatin sites, RBFOX splicing factors' role in thymic epithelial cells, and more.